natgillin/translations-raw huggingface dataset:
Four metabolic pathways have been identified in vivo, none of which accounted for more than 6.5% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission.
In vivo su utvrđena četiri metabolička puta, od kojih nijednim nije prošlo više od 6,5% doze: dealkilacija, hidroksilacija, hidrogenacija i razgradnja benzisoksazola.
four MIRAPEXIN 0.26 mg prolonged-release tablets.
četiri MIRAPEXIN 0,26 tablete s produljenim oslobađanjem.
Four multicentre, double-blind, placebo-controlled obesity Phase 3 studies (NB-301, NB-302, NB-303 and NB-304) were conducted to evaluate the effect of naltrexone / bupropion in conjunction with lifestyle modification in 4,536 subjects randomised to naltrexone/bupropion or placebo.
Četiri multicentrična, dvostruko slijepa, placebom kontrolirana ispitivanja pretilosti faze 3 (NB-301, NB-302, NB-303 i NB-304) su provedena kako bi se procijenio učinak naltrekson / bupropiona uz promjene stila života u 4536 ispitanika randomiziranih na naltrekson / bupropion ili placebo.
Four of these seven GIST patients discontinued treatment following first observation of DVT.
Četiri od spomenutih sedam bolesnika s GIST-om prekinulo je liječenje nakon prve pojave simptoma DVT-a.
four Oprymea 0.26 mg prolonged-release tablets.
četiri Oprymea 0,26 tablete s produljenim oslobađanjem.
Four or more NRTI- associated mutations
Četiri ili više mutacija povezanih s NRTI
Four other studies compared Edistride with placebo, when used as an add-on to either metformin, a sulphonylurea (glimepiride), a thiazolidinedione or insulin in 2,370 patients.
U četiri druga ispitivanja Edistride je uspoređen s placebom, kada se lijek koristio kao dodatna terapija uz metformin, sulfonilureu (glimepirid), tijazolidinedion ili inzulin u 2 370 bolesnika.
Four patients in the TOBI Podhaler treatment group experienced significant decreases in hearing which were transient in three patients and persistent in one case.
Četiri su bolesnika u terapijskoj skupini koja je primala TOBI Podhaler doživjela značajan gubitak sluha koji je bio prolazan u tri bolesnika, a trajan u jednog bolesnika.
Four patients with severe renal impairment (creatinine clearance 12 to 30 mL/min) were included in the data set.
U skupinu podataka bila su uključena četiri bolesnika s teškim oštećenjem bubrega (klirens kreatinina 12 do 30 ml/min).
Four per cent (4%) of patients treated with Tecfidera discontinued due to gastrointestinal events.
Četiri posto (4%) bolesnika liječenih Tecfiderom prekinulo je liječenje zbog gastrointestinalnih smetnji.
Four placebo-controlled phase III studies in plaque psoriasis were pooled to evaluate the safety of Cosentyx in comparison to placebo up to 12 weeks after treatment initiation.
Četiri placebom kontrolirana ispitivanja faze III za plak psorijazu bilo je objedinjeno da bi se ocijenila sigurnost Cosentyxa u usporedbi s placebom do 12 tjedana nakon početka liječenja.
Four pump actuations
četiri pokretanja pumpice
four pump actuations
četiri potiska pumpice
four SIFROL 0.26 mg prolonged-release tablets.
četiri SIFROL 0,26 tablete s produljenim oslobađanjem.
Four studies have evaluated the effects of pertuzumab on the PK of co-administered cytotoxic agents, docetaxel, gemcitabine, erlotinib and capecitabine.
U četiri su ispitivanja ispitani učinci pertuzumaba na farmakokinetiku istodobno primijenjenih citotoksičnih lijekova: docetaksela, gemcitabina, erlotiniba i kapecitabina.
Four subjects (26.7%) on the recommended teduglutide dose achieved at least a three-day reduction in parenteral nutrition needs.
Četiri ispitanika (26,7%) na preporučenoj dozi teduglutida postigla su umanjenje potrebe za parenteralnom prehranom od najmanje tri dana.
Four subjects had previously received an unsuccessful stem cell transplant from a haploidentical donor and 15 of 18 subjects had previously received prior enzyme replacement therapy with polyethylene-glycol-modified bovine adenosine deaminase (PEG-ADA).
Četiri ispitanika prethodno su neuspješno bila podvrgnuta presađivanju matičnih stanica od haploidentičnog davatelja, dok je 15 od 18 ispitanika prethodno primalo nadomjesnu enzimsku terapiju goveđom adenozin deaminazom modificiranom polietilenglikolom (engl. polyethylene-glycol-modified bovine adenosine deaminase, PEG-ADA).
Four subjects in the unboosted REYATAZ group and 2 in the REYATAZ + ritonavir group had HIV RNA > 500 copies/ml during the maintenance phase.
Četiri ispitanika liječena nepojačanim lijekom REYATAZ i 2 u skupini koja je primala REYATAZ + ritonavir imala su HIV RNK > 500 kopija/ml tijekom faze održavanja.
Four thousand six hundred and twenty eight (4,628) patients were randomised and treated for up to 30 months maximum (median follow-up: 22 months) with either dronedarone 400 mg twice daily (2,301 patients) or placebo (2,327 patients), in addition to conventional therapy including beta-blockers (71%), ACE inhibitors or AIIRAs (69%) digitalis (14%), calcium antagonists (14%), statins (39%), oral anticoagulants (60%), chronic antiplatelet therapy (6%) and/or diuretics (54%).
Randomizirano je 4628 bolesnika koji su tijekom najviše 30 mjeseci (medijan praćenja: 22 mjeseca) primali dronedaron u dozi od 400 mg dvaput na dan (2301 bolesnik) ili placebo (2327 bolesnika) kao dodatak standardnoj terapiji koja je uključivala beta-blokatore (71%), ACE inhibitore ili antagoniste receptora angiotenzina II (69%), digitalis (14%), antagoniste kalcija (14%), statine (39%), oralne antikoagulanse (60%), kroničnu terapiju antitromboticima (6%) i/ili diuretike (54%).
Four treatment cycles of this combination are administered.
Primjenjuje se 4 ciklusa ovog kombiniranog liječenja.
Four treatment cycles of this combination are administered.
Primjenjuju se 4 ciklusa ovog kombiniranog liječenja.
Four weeks after finishing this first treatment, your doctor will assess your skin.
Četiri tjedna nakon završetka prvog ciklusa liječenja Vaš će liječnik procijeniti stanje vaše kože.
Four weeks after the final injection, 96% of these people who received both doses of Ixiaro had developed protective levels of antibodies (352 out of 365).
Četiri tjedna nakon posljednje injekcije 96 % tih osoba koje su primile obje doze lijeka Ixiaro razvilo je zaštitne razine protutijela (352 od 365).
Four-week-old chickens from the group of one-day-old vaccinated chicks were challenged with ND virus and Vectormune ND provided protection in 95% of the chickens compared with 0–10% in the non-vaccinated group.
Četiri tjedna stari pilići iz grupe jedan dan starih cijepljenih pilića izazvani su virusom newcastelske bolesti, te je Vectormune ND zaštitio 95% pilića u usporedbi s 0-10% onih u necijepljenoj grupi.
Four-week-old chickens from vaccinated eggs were challenged with ND virus and 86% of the chickens were protected compared with 0–10% in the unvaccinated group.
Četiri tjedna stari pilići iz grupe cijepljenih jaja izazvani su virusom newcastelske bolesti, te je 86% pilića bilo zaštićeno u usporedbi s 0-10% pilića u necijepljenoj grupi.
Fourteen days after administration the mean cefovecin concentration in plasma was 18 g/ml.
Četrnaest dana nakon primjene srednja koncentracija cefovecina u plazmi bila je 18 g/ml.
Fourteen days after administration, the mean cefovecin concentration in plasma was 5.6 μg/ml.
Četrnaest dana nakon primjene srednja koncentracija cefovecina u plazmi bila je 5,6 g/ml.
Fourteen metabolites have been identified in plasma, urine and feces; all but one were also metabolised by CYP3A.
Identificirano je 14 metabolita u plazmi, urinu i fecesu; svi osim jednog također se metaboliziraju putem CYP3A.
Fourteen patients aged ≥ 12 to < 18 years with homozygous familial hypercholesterolaemia were included in clinical studies.
Četrnaest bolesnika u dobi ≥ 12 do < 18 godina s homozigotnom obiteljskom hiperkolesterolemijom je bilo uključeno u klinička ispitivanja.
Fourteen primary pathways have been identified of which O-demethylation and N-dealkylation are the most important.
Identificirano je četrnaest primanih putova od kojih su najznačajniji O-demetilacija i N-dealkilacija.
Fourth
Četvrta
Fourth dose: 12 months after the first dose
Četvrta doza: 12 mjeseci nakon prve doze
Fourth injection - 6 months after the first injection.
Četvrta injekcija - 6 mjeseci nakon prve injekcije.
FPG (mmol/L)
GUP natašte (mmol/l)
FPV (PLI IV)....................................................................................................................  103.5 CCID50.
FPV (PLI IV).....................................................................................................................  103,5 CCID50
FPV (PLI IV)....................................................................................................................  103.5 CCID50.
FPV (PLI IV).....................................................................................................................  103,5 CCID50.
FPV (PLI IV).....................................................................................................................  103.5 CCID50
FPV (PLI IV).....................................................................................................................  103,5 CCID50
FPV/RTV BID vs LPV/RTV BID
FPV/RTV BID naspram LPV/RTV BID
FPV/RTV BID – Fosamprenavir with ritonavir twice daily, LPV/RTV BID – Lopinavir / ritonavir twice daily
FPV/RTV BID – Fosamprenavir s ritonavirom 2 puta dnevno, LPV/RTV BID – Lopinavir/ritonavir 2 puta dnevno
FPV/RTV)
Halofantrin
FPV/RTV)
IMUNOSUPRESIVI
FPV/RTV)
interakcija lijeka.
FR-31000 Toulouse Cedex France
FR-31000 Toulouse Cedex Francuska
fraction
transaminaze
Fraction absorbed transmucosally
Frakcija apsorbirana kroz sluznicu
Fracture
lomovi
Fracture adverse events of long bones in the lower extremities were reported in approximately 24% (femur) and 14% (tibia) of zoledronic acid-treated patients vs 12% and 5% of pamidronate-treated patients with severe osteogenesis imperfecta, regardless of disease type and causality but overall incidence of fractures was comparable for the zoledronic acid and pamidronate-treated patients: 43% (32/74) vs 41% (31/76).
Nuspojava prijeloma dugih kostiju donjih ekstremiteta bila je prijavljena u približno 24% (bedrena kost) i 14% (goljenična kost) bolesnika liječenih zoledronatnom kiselinom naspram 12% odnosno, 5% u bolesnika s teškim oblikom osteogenesis imperfecta liječenih pamidronatom, bez obzira na tip bolesti i uzrok, no ukupna incidencija prijeloma bila je slična u bolesnika liječenih zoledronatnom kiselinom i onih liječenih pamidronatom: 43% (32/74) naspram 41% (31/76).
Fracture bone
Prijelom kosti
fracture bone4
prijelom kosti4
fracture bone4
prijelom kosti5
fracture bone5
prijelom kosti5
Fracture Incidence in Postmenopausal Women:
Incidencija prijeloma u žena u postmenopauzi
Fracture incidence was evaluated as a safety endpoint.
Kao mjera ishoda za sigurnost primjene procjenjivala se incidencija prijeloma.
Fractures
Frakture
Fractures of the shin bone
Prijelomi goljenične kosti
Fractures*
Prijelomi
fractures†
kostima, bol u
fragility fracturesc
prijelomi zbog krhkostic (kuk, palčana
Fragments of the virus strains that are expected to cause flu in the upcoming season, according to the recommendations from the WHO for the northern hemisphere and from the European Union (EU), need to be included in Intanza before the vaccine can be used.
Fragmenti sojeva virusa za koje se očekuje da će prouzročiti gripu u nadolazećoj sezoni, u skladu s preporukama SZO-a za sjevernu hemisferu kao i preporukama Europske unije (EU), moraju biti dodani cjepivu Intanza prije korištenja.
Frail patients, including patients at risk for malnutrition, patients with recent cardiovascular events and patients with moderate to severe cognitive impairment were excluded.
Slabiji bolesnici, uključujući bolesnike u riziku od malnutricije, bolesnike s nedavnim kardiovaskularnim događajima te bolesnike s umjerenim do teškim kognitivnim oštećenjem, bili su isključeni iz ispitivanja.
Framingham, MA 01701-9322 USA
MA 01701-9322 SAD
FRANCE
171 21 Solna
France
AbbVie, Lda.
FRANCE
Francuska.
France
Francuska/France
FRANCE
Puławska 314
France Manufacturer responsible for batch release:
Francuska Proizvođač odgovoran za puštanje serije lijeka u promet
France Portugal
Portugal
France, Germany
Francuska, Njemačka
France.
Francuska.
France‌‌
Francuska
Free elastase was unmeasurably low in all samples.
Slobodna elastaza bila je nemjerljivo niska u svim uzorcima.
Free non-bound Lutetium-177 should be consequently minimised.
Posljedično, slobodni nevezani lutecij-177 mora se minimizirati.
freeze or use the Repatha pre-filled pen if it has been frozen.
zamrzavati ili koristiti Repatha napunjenu brizgalicu koja je bila zamrznuta.
Frequenc y
Učestalost
Frequencies
Učestalosti
Frequencies are based on all grades and defined as: very common (≥1/10), common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100).
Učestalost se temelji na svim stupnjevima i definira se kao: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10); manje često (≥ 1/1000 do < 1/100).
Frequencies are based on all grades and defined as: very common (≥1/10), common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100).
Učestalost se temelji na svim stupnjevima i definira se kao: vrlo često (≥1/10), često (≥1/100 i<1/10); manje često (≥1/1000 i<1/100).
Frequencies are based on all grades and defined as: very common (≥1/10), common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100).
Učestalost se temelji na svim stupnjevima i definiraa se kao: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10); manje često (≥ 1/1000 do < 1/100).
Frequencies are based on all grades and defined as: very common (≥1/10), common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Kategorije učestalosti se temelje na nuspojavama svih stupnjeva i definirane su na sljedeći način: vrlo često (≥ 1/10); često (≥ 1/100 i < 1/10); manje često (≥ 1/1000 i < 1/100); rijetko (≥ 1/10 000 i < 1/1000); vrlo rijetko (<1/10 000); nepoznato (učestalost se ne može procijeniti iz dostupnih podataka).
Frequencies are based on all grades and defined as: very common (≥1/10), common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Učestalost pojavljivanja temelji se na svim stupnjevima, a definirana je kao: vrlo često (≥ 1/10); često (≥ 1/100 i < 1/10); manje često (≥ 1/1000 i < 1/100); rijetko (≥ 1/10 000 i < 1/1000); vrlo rijetko (< 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Frequencies are defined according to the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to
Učestalost je definirana prema sljedećoj konvenciji: vrlo često (≥1/10); često (≥1/100 do <1/10); manje često (≥1/1000 do
Frequencies are defined according to the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
Za učestalost pojavljivanja korištena je sljedeća kategorizacija: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Frequencies are defined according to the following convention: very common ( 1/10); common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100), rare ( 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Učestalosti su definirane na sljedeći način: vrlo često ( 1/10), često ( 1/100 i < 1/10), manje često ( 1/1000 i < 1/100), rijetko ( 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
Frequencies are defined as common (≥ 1/100 to < 1/10) or uncommon (≥ 1/1,000 to < 1/100).
Učestalost je definirana kao često (≥ 1/100 do < 1/10) ili manje često (≥ 1/1000 do < 1/100).
Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) or rare (≥ 1/10,000 to < 1/1,000).
Učestalosti su definirane kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100) ili rijetko (≥ 1/10 000 i < 1/1000).
Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to
Učestalosti su definirane kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i
Frequencies are defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1000 to < 1/100); rare (≥ 1/10,000 to <1/1,000); very rare (< 1/10,000) or not known (cannot be estimated from available data).
Učestalost je definirana kako slijedi: vrlo često (1/10); često (1/100 i 1/10); manje često (1/1000 i 1/100); rijetko (1/10 000 i 1/1000); vrlo rijetko (<1/10 000) ili nepoznato (ne može se procijeniti iz dostupnih podataka).
Frequencies are defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1000 to < 1/100); rare (≥ 1/10,000 to <1/1,000); very rare (< 1/10,000) or not known (cannot be estimated from available data).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10); često (≥ 1/100 i < 1/10); manje često (≥ 1/1000 i < 1/100); rijetko (≥ 1/10 000 i < 1/1000); vrlo rijetko (<1/10 000) ili nepoznato (ne može se procijeniti iz dostupnih podataka).
Frequencies are defined as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) or very rare (<1/10,000).
Učestalost je definirana kao: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000) ili vrlo rijetko (< 1/10 000).
Frequencies are defined as follows: Very common: (≥1/10) Common: (≥1/100 to <1/10)
Učestalosti su definirane na sljedeći način: Vrlo često: (≥ 1/10)
Frequencies are defined as very common (> 1/10), common (> 1/100 to < 1/10), uncommon (> 1/1000 to < 1/100), rare (> 1/10,000 to
Učestalosti su definirane kao vrlo česte (>1/10), česte (>1/100 do <1/10), manje česte (>1/1000 do
Frequencies are defined as very common (>1/10), common (>1/100 to <1/10), uncommon (>1/1,000 to <1/100), rare (>1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Učestalosti su definirane kao: vrlo često (>1/10), često (>1/100 do <1/10), manje često (>1/1000 do <1/100), rijetko (>1/10 000 do <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Frequencies are defined as very common (>1/10), common (>1/100 to <1/10), uncommon (>1/1,000 to <1/100), rare (>1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Učestalosti su definirane kao: vrlo često (>1/10), često (>1/100 do <1/10), manje često (>1/1000 do <1/100), rijetko (>1/10 000 to <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz postojećih podataka).
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1,000 to < 1/100).
Učestalosti su definirane kao vrlo česte (≥ 1/10), česte (≥ 1/100 i < 1/10) i manje česte (≥ 1/1 000 i < 1/100).
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), or very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Učestalosti su definirane kao: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1000), ili vrlo rijetko (< 1/10 000), nije poznato (ne može se procijeniti iz dostupnih podataka).
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Učestalosti su definirane kao vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1,000) , not known (cannot be estimated from the available data).
Učestalost je definirana kategorijama vrlo često (1/10), često (1/100 do 1/10), manje često (1/1000 do 1/100), rijetko (1/10 000 do 1/1000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100, < 1/10) or not known (identified through post-marketing safety surveillance and the frequency cannot be estimated from the available data).
Učestalosti su definirane kao vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), ili nepoznato (identificirane tijekom praćenja nakon stavljanja lijeka u promet, a učestalost se ne može procijeniti iz dostupnih podataka).
Frequencies are defined as very common (≥1/10), common (≥1/100 to
Učestalost se definira kao vrlo često (≥1/10), često (≥1/100 i
Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100) and very rare (<1/10,000).
Kategorije učestalosti definirane su kao vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100) i vrlo rijetko (< 1/10 000).
Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), and very rare (<1/10,000).
Kategorije učestalosti definirane su kao vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100) i vrlo rijetko (< 1/10 000).
Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (1/10,000 to <1/1,000), very rare (<1/10,000), and not known (cannot be estimated from the available data).
Učestalosti su definirane kao vrlo često (≥1/10), često (≥1/100 do <1/10), manje često (≥1/1.000 do <1/100), rijetko (≥1/10.000 do <1/1.000), vrlo rijetko (<1/10.000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
Frequencies are defined as very common (≥1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to
Učestalosti su definirane kao: vrlo često (>1/10), često (>1/100, <1/10), manje često (>1/1000, <1/100), rijetko (>1/10000, <1/1000), vrlo rijetko (<1/10000).
Frequencies are defined as very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from available data).
Učestalosti su definirane kao vrlo često (≥1/10); često (≥1/100 i <1/10); manje često (≥1/1000 i <1/100); rijetko (≥1/10 000 i <1/1000); vrlo rijetko (<1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Frequencies are defined as very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Učestalost pojavljivanja definirana je kao: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Frequencies are defined as very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1000 to < 1/100), rare ( 1/10,000 to < 1/1000), very rare (< 1/10,000).
Učestalost je definirana kao vrlo često ( 1/10), često ( 1/100 i < 1/10), manje često ( 1/1000 i < 1/100), rijetko ( 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000).
Frequencies are defined as very common (1/10), common (1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (1/10,000 to <1/1,000), very rare (<1/10,000).
Učestalost je definirana kao vrlo često (1/10), često (1/100 i <1/10), manje često (1/1000 i <1/100), rijetko (1/10 000 i <1/1000), vrlo rijetko (<1/10 000).
Frequencies are defined as: very common (≥ 1/10) common (≥ 1/100 to < 1/10)
Učestalosti su definirane kao: vrlo često (≥ 1/10)